 |
|
Researchers disprove long-standing belief about HIV treatment
July 25, 2008WINSTON-SALEM, N.C. - Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."
Hepatitis C (HCV) infection is more serious in HIV-infected people, leading to rapid liver damage, according to the Centers for Disease Control. Intravenous drug use is a main method of contraction for both HIV and HCV and 50 to 90 percent of HIV-infected drug users are also infected with HCV.
The Wake Forest Baptist study looked at whether having HCV co-infection impairs immune restoration in patients receiving highly active anti-retroviral therapy (HAART) to suppress their HIV infection. The results appear in the July issue of AIDS Research and Human Retroviruses.
The research focused on levels of CD4 cells, the specific type of immune cell that is attacked by the HIV virus, and their ability to rebuild after HIV is suppressed.
"We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4," said Marina Nunez, M.D., lead researcher and an assistant professor of infectious diseases. "Some studies suggested it was because of the hepatitis C. This study says it's not the presence of active hepatitis C replication."
Thus, said Nunez, genetic factors involved in the immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors might explain the blunted immune restoration observed in some co-infected patients. "Research efforts should pursue the role of those other factors in the immune restoration," she said.
"From a clinical standpoint, although these findings will not alter the clinical management of HIV-HCV-co-infected patients, they make clear that even after successful treatment of the HCV infection, some patients may still not get an adequate CD4 recovery under HIV treatment."
For the retrospective study, researchers examined existing medical records of 322 patients from two separate databases - one from Madrid, Spain, and the other from Wake Forest University Baptist Medical Center. Patients were separated into two groups - those co-infected with hepatitis C and HIV and those infected only with HIV. Researchers reviewed CD4 levels at baseline (before beginning HIV suppression) and every year after for up to three years, while the patients continuously received HAART, an HIV treatment consisting of three different types of medicines used by many patients, and formerly referred to as the HIV "cocktail."
Years of clinical experience have shown that, with HAART treatment suppressing the HIV, CD4 levels are typically able to restore themselves, Nunez said.
However, in some patients, it has been observed that the immune restoration is poorer after HAART. Therefore, Nunez said, it has been a common practice for doctors to attribute less than desirable CD4 restoration after HAART in co-infected patients to the hepatitis C virus.
Studies to date have found evidence both in support of and against this belief, Nunez said. But a limitation in previous studies has been that co-infected patients have been identified by the presence of HIV and the hepatitis C antibody. Since many patients with hepatitis C clear the active virus but continue to carry the antibody, there hasn't been a pure sample of patients truly co-infected with both active viruses to analyze. In this study, only patients with HIV and active hepatitis C cell replication, therefore active virus, were classified as "co-infected."
The study found that there is no difference in the CD4 restoration of co-infected patients and mono-infected patients. However, it did show some differences that seem to be associated with age, gender or past intravenous drug use.
"The purpose of this study was to find out if hepatitis C was impeding the CD4 restoration in co-infected patients," Nunez said. "And it does not. There are other factors doing it. This study says that you can look into those other factors, but we cannot blame the hepatitis C anymore."
Wake Forest University Baptist Medical Center
The research focused on levels of CD4 cells, the specific type of immune cell that is attacked by the HIV virus, and their ability to rebuild after HIV is suppressed.
"We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4," said Marina Nunez, M.D., lead researcher and an assistant professor of infectious diseases. "Some studies suggested it was because of the hepatitis C. This study says it's not the presence of active hepatitis C replication."
Thus, said Nunez, genetic factors involved in the immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors might explain the blunted immune restoration observed in some co-infected patients. "Research efforts should pursue the role of those other factors in the immune restoration," she said.
"From a clinical standpoint, although these findings will not alter the clinical management of HIV-HCV-co-infected patients, they make clear that even after successful treatment of the HCV infection, some patients may still not get an adequate CD4 recovery under HIV treatment."
For the retrospective study, researchers examined existing medical records of 322 patients from two separate databases - one from Madrid, Spain, and the other from Wake Forest University Baptist Medical Center. Patients were separated into two groups - those co-infected with hepatitis C and HIV and those infected only with HIV. Researchers reviewed CD4 levels at baseline (before beginning HIV suppression) and every year after for up to three years, while the patients continuously received HAART, an HIV treatment consisting of three different types of medicines used by many patients, and formerly referred to as the HIV "cocktail."
Years of clinical experience have shown that, with HAART treatment suppressing the HIV, CD4 levels are typically able to restore themselves, Nunez said.
However, in some patients, it has been observed that the immune restoration is poorer after HAART. Therefore, Nunez said, it has been a common practice for doctors to attribute less than desirable CD4 restoration after HAART in co-infected patients to the hepatitis C virus.
Studies to date have found evidence both in support of and against this belief, Nunez said. But a limitation in previous studies has been that co-infected patients have been identified by the presence of HIV and the hepatitis C antibody. Since many patients with hepatitis C clear the active virus but continue to carry the antibody, there hasn't been a pure sample of patients truly co-infected with both active viruses to analyze. In this study, only patients with HIV and active hepatitis C cell replication, therefore active virus, were classified as "co-infected."
The study found that there is no difference in the CD4 restoration of co-infected patients and mono-infected patients. However, it did show some differences that seem to be associated with age, gender or past intravenous drug use.
"The purpose of this study was to find out if hepatitis C was impeding the CD4 restoration in co-infected patients," Nunez said. "And it does not. There are other factors doing it. This study says that you can look into those other factors, but we cannot blame the hepatitis C anymore."
Wake Forest University Baptist Medical Center
Hepatitis Current Events and Hepatitis News RSSA new light on the anti-tumor mechanisms of Scutellaria barbata
Medicinal plants have been used as traditional remedies for hundreds of years. Among them, S. barbata has been traditionally used in treatment of hepatitis, inflammation, osteomyelitis and gynecological diseases in China.
May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations.
How to tell if a hepatitis-C-virus-infected patient will respond to therapy
Hepatitis C virus (HCV) causes hepatitis and increased risk of developing liver cancer. Current treatments are expensive, have severe side effects, and fail in about half the patients treated.
Using math to understand hep. C: Patterns paint picture of who will respond to treatment
Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered.
Hepatitis C Treatment Reduces the Virus but Liver Damage Continues
Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.
Leeds research points to new therapy for hepatitis C treatment
Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds.
Interferon as long-term treatment for hepatitis C not effective, report HALT-C researchers
Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.
Childhood vaccines cause financial burden to many health care providers
The costs that health care providers are charged and reimbursed for childhood vaccines vary widely, and the high cost of some immunizations is leading to significant financial strain for some physicians, according to a pair of new studies from the University of Michigan Health System.
Antibiotics: Single largest class of drugs causing liver injury
Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute.
Study unmasks how ovarian tumors evade immune system
Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked
More Hepatitis Current Events and Hepatitis News Articles
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition,... |
 | Herbs for Hepatitis C and the Liver (A Storey Medicinal Herb Guide) by Stephen Harrod Buhner An insightful overview of the impending Hepatitis C epidemic, its causes, the most recent research, and an in-depth, detailed look at the botanical medicines that show promising results for restoring liver function. Includes formulas for using herbs to strengthen the liver and combat... |
 | Hepatitis C Cookbook: Easy and Delicious Recipes by Heather Jeanne Hepatitis C is a potentially fatal virus that attacks the liver. According to the Centers for Disease Control, Hepatitis C has already infected an estimated four to five million Americans, and worldwide it may have infected as many as 200 million. Most experts agree that if the rate of Hepatitis C infection isn’t curbed soon, it will eventually kill more people each year than AIDS. However,... |
 | Triumph Over Hepatitis C by Lloyd Wright This is the third edition, 2nd printing. This edition of Triumph Over Hepatitis C includes all new information updates. It is important for the reader to understand that HCV has not changed, the way to health has not changed. The only thing that has changed is Big Pharm's quest for your money and their complete disregard for your... |
 | Living with Hepatitis C: A Survivor's Guide, Fourth Edition by Gregory T. Everson, Hedy Weinberg "An extremely useful title…recommended."—Library JournalLiving with Hepatitis C was the first book to explain in everyday language the causes of the disease, the major and minor symptoms, and all of the latest treatments, including pegylated interferons. Since its first publication, researchers have made dramatic strides in helping the millions of Americans who suffer from this deadly... |
 | Hepatitis B: The Hunt for a Killer Virus by Baruch S. Blumberg About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And... |
 | The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing by Misha Ruth Cohen, Robert Gish, Kalia Doner A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no... |
 | Living With Hepatitis C For Dummies by Nina L. Paul A comprehensive, empathetic guide for anyone suffering from this serious liver disease Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths–about 8,000 to 10,000 people annually–and is the most common reason for liver... |
 | The First Year: Hepatitis C: An Essential Guide for the Newly Diagnosed (First Year, The) by Cara Bruce, Lisa Montanarelli The fifth-year anniversary of the book ushers in a new phase of treatment and information, including protease inhibitors (which have been so successful in treating HIV), split-liver transplants, and prophylactic and therapeutic vaccines for HCV. Bruce and Montanarelli also offer updated information on medications that are toxic to the liver; Eastern and Western approaches to healing; nutrition... |
 | Living with Hepatitis B: A Survivor's Guide by Gregory T. Everson, Hedy Weinberg, Steve Bingham A new book from the authors of the bestselling Living with Hepatitis C. Chronic hepatitis B, a condition that currently affects 1.25 to 1.5 million Americans, is a serious progressive disease that can lead to cirrhosis, liver cancer, the need for liver transplantation and death. According to the Centers for Disease Control, more than 200,000 Americans of all ages are infected each year with the... |
| © 2009 BrightSurf.com |